when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GILEAD SCIENCES INC · news · pharmadog

← back to GILEAD SCIENCES INC

News mentioning GILEAD SCIENCES INC

84 stories

Sep 24, 26STAT+: Why Gilead can’t stop talking about its ambitions in immunologystat

Sep 18, 26Electra lights up with $350M IPO for pivotal immune-disease drug developmentbiospace

Sep 17, 26DPHARM: How to address the clinical trial enrollment crisis?fiercebiotech

Sep 16, 26Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPOendpoints

Sep 15, 26WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightbiopharma dive

Sep 14, 26Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonfiercebiotech

Sep 11, 26Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra usebiopharma dive

Sep 10, 26Tyra shares slip as bladder cancer responses fall short of investor expectationsbiospace

Sep 9, 26CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’fiercebiotech

Sep 9, 26BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’biospace

Sep 4, 26This week in charts: China deals, stock flatlines and Lilly’s M&A spreebiopharma dive

Sep 1, 26ArsenalBio sheds most of staff in pivot to in vivo CAR-Tfiercebiotech

Aug 28, 26Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccinesbiopharma dive

Aug 27, 26Gilead gets another HIV treatment approval, extending lenacapavir's dominanceendpoints

Aug 25, 26Labcorp launches new hepatitis D test to find patients with most severe form of virusfiercebiotech

Aug 20, 267 biopharma M&A deals where layoffs followedbiospace

Aug 12, 26Boulevard starts up with $65M to pursue targeted autoimmune drugsbiopharma dive

Aug 5, 26Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchbiopharma dive

Aug 5, 26Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mountsbiospace

Aug 5, 26STAT+: Moderna launches early trial of Ebola mRNA vaccinestat

Aug 5, 264 potential biotech M&A targets, plus a pretty sure bet from J&Jbiospace

Aug 4, 26STAT+: Three biotechs with three news updatesstat

Aug 4, 26STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and morestat

Aug 3, 26STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate casestat

Jul 30, 26J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutfiercebiotech

Jul 28, 26Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialfiercebiotech

Jul 27, 26Legend Biotech CEO abruptly steps down without permanent replacementfiercebiotech

Jul 24, 26Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsfiercebiotech

Jul 24, 26Merck stages expanded access to monthly HIV PrEP pill ahead of approvalfiercebiotech

Jul 23, 26Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onbiospace

← prevpage 2 of 3next →